1. What is the decision or change (e.g. clinical topic, practice guideline, system design, delivery of care) you are facing or struggling with where a summary of the evidence would be helpful?

Questions: What is the utility of blood type testing and administration of RH immunoglobulin in early pregnancy?

Population: individuals who are pregnant up to 12 weeks and having bleeding, including in normal early pregnancy, during miscarriage, and undergoing medication or procedural abortion

Intervention: Rh testing and RH-immunoglobulin administration for pregnant RH negative individuals

Comparator: No Rh testing or Rh immunoglobulin administration for pregnant RH negative individuals

Outcomes: adverse effects, cost, future pregnancy outcomes

Setting: ambulatory

2. Why are you struggling with this issue?

There is variation in what healthcare providers are doing in practice and what medical societies recommend

3. What do you want to see changed? How will you know that your issue is improving or has been addressed?

I would like to do away with recommendations for Rh testing and Rh immunoglobulin testing in early pregnancy as this causes unnecessary health barriers, anxiety, use of human-derived blood product, without evidence of benefit

4. When do you need the evidence report?

Sat, 03/22/2025

5. What will you do with the evidence report?

We will use the evidence report to influence medical societies including the American College of Obstetricians and Gynecologists to support the appropriate recommendation

Supporting Documentation

Induced Abortion and the Risk of Rh Sensitization (PDF, 398 KB)

Optional Information About You

What is your role or perspective? Physician

If you are you making a suggestion on behalf of an organization, please state the name of the organization University of Pennsylvania

May we contact you if we have questions about your nomination? Yes